FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Renaud Capdeville

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Herlinde Dumez; Helen Gall; Renaud Capdeville; Catherine Dutreix; Allan T van Oosterom; Giuseppe Giaccone
A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer.
Heinz Schmidli; Bin Peng; Gilles-Jacques Riviere; Renaud Capdeville; Martee Hensley; Insa Gathmann; Ann E Bolton; Amy Racine-Poon
Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.
Martin A Champagne; Renaud Capdeville; Mark Krailo; Wenchun Qu; Bin Peng; Marianne Rosamilia; Martine Therrien; Ulrike Zoellner; Susan M Blaney; Mark Bernstein
Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Renaud Capdeville (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Herlinde Dumez; Helen Gall; Renaud Capdeville; Catherine Dutreix; Allan T van Oosterom; Giuseppe Giaccone
A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer.
Anti-cancer drugs 2007;18(2):219-25.
2005: Heinz Schmidli; Bin Peng; Gilles-Jacques Riviere; Renaud Capdeville; Martee Hensley; Insa Gathmann; Ann E Bolton; Amy Racine-Poon
Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.
British journal of clinical pharmacology 2005;60(1):35-44.
2004: Martin A Champagne; Renaud Capdeville; Mark Krailo; Wenchun Qu; Bin Peng; Marianne Rosamilia; Martine Therrien; Ulrike Zoellner; Susan M Blaney; Mark Bernstein
Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study.
Blood 2004;104(9):2655-60.
2004: Catherine Dutreix; Bin Peng; Guenther Mehring; Michael Hayes; Renaud Capdeville; Rolf Pokorny; Michael Seiberling
Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects.
Cancer chemotherapy and pharmacology 2004;54(4):290-4.
2004: Zariana Nikolova; Bin Peng; Martine Hubert; Michael Sieberling; Urs Keller; Yu-Yun Ho; Horst Schran; Renaud Capdeville
Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules.
Cancer chemotherapy and pharmacology 2004;53(5):433-8.
2004: Marlene A Dressman; Rachel Malinowski; Lee Anne McLean; Insa Gathmann; Renaud Capdeville; Martee Hensley; Mihael H Polymeropoulos
Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571).
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(7):2265-71.
2004: Bin Peng; Michael Hayes; Debra Resta; Amy Racine-Poon; Brian J Druker; Moshe Talpaz; Charles L Sawyers; Marianne Rosamilia; John Ford; Peter Lloyd; Renaud Capdeville
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):935-42.
2004: Miklos Pless; Karim Belhadj; Hans D Menssen; Wolfgang Kern; Bertrand Coiffier; Jürgen Wolf; Richard Herrmann; Eckhard Thiel; Doug Bootle; Ivo Sklenar; Christian Müller; Les Choi; Carl Porter; Renaud Capdeville
Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with relapsed or refractory non-Hodgkin's lymphoma: results from a phase II multicenter study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(4):1299-305.
2004: Bin Peng; Catherine Dutreix; Gunther Mehring; Michael J Hayes; Monique Ben-Am; Michael Seiberling; Rolf Pokorny; Renaud Capdeville; Peter Lloyd
Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion.
Journal of clinical pharmacology 2004;44(2):158-62.
2004: Ann E Bolton; Bin Peng; Martine Hubert; Axel Krebs-Brown; Renaud Capdeville; Urs Keller; Michael Seiberling
Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
Cancer chemotherapy and pharmacology 2004;53(2):102-6.
2004: Lee Anne McLean; Insa Gathmann; Renaud Capdeville; Mihael H Polymeropoulos; Marlene A Dressman
Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):155-65.
2003: Stephen G O'Brien; P Meinhardt; E Bond; J Beck; B Peng; Catherine Dutreix; G Mehring; S Milosavljev; C Huber; Renaud Capdeville; T Fischer
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia.
British journal of cancer 2003;89(10):1855-9.
2003: Renaud Capdeville; Sandra Silberman
Imatinib: a targeted clinical drug development.
Seminars in hematology 2003;40(2 Suppl 2):15-20.
2003: Stephen G O'Brien; françois guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan Lanng Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Andrew Lamb; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
The New England journal of medicine 2003;348(11):994-1004.
2002: Catherine J Wu; Donna Neuberg; Antoinette Chillemi; Stephen McLaughlin; Ephraim P Hochberg; Ilene Galinsky; Daniel J DeAngelo; Robert J Soiffer; Edwin P Alyea; Renaud Capdeville; Richard M Stone; Jerome Ritz
Quantitative monitoring of BCR/ABL transcript during STI-571 therapy.
Leukemia & lymphoma 2002;43(12):2281-9.
2002: Oliver G Ottmann; Brian J Druker; Charles L Sawyers; John M Goldman; Josy Reiffers; Richard T Silver; Sante Tura; Thomas Fischer; Michael W N Deininger; Charles Alan Schiffer; Michele Baccarani; Alois Gratwohl; Andreas Hochhaus; Dieter Hoelzer; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Stephen G O'Brien
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
Blood 2002;100(6):1965-71.
2002: Renaud Capdeville; Sandra Silberman; Sasa Dimitrijevic
Imatinib: the first 3 years.
European journal of cancer (Oxford, England : 1990) 2002;38 Suppl 5():S77-82.
2002: Michael O'Dwyer; Michael J Mauro; Gwen Kurilik; Motomi Mori; Suzanne Balleisen; Susan B Olson; Ellen Magenis; Renaud Capdeville; Brian J Druker
The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.
Blood 2002;100(5):1628-33.
2002: George D Demetri; Margaret von Mehren; Charles D Blanke; Annick D Van den Abbeele; Burton L Eisenberg; Peter J Roberts; Michael C Heinrich; David A Tuveson; Samuel Singer; Milos J Janicek; Jonathan A Fletcher; Stuart G Silverman; Sandra Silberman; Renaud Capdeville; Beate Kiese; Bin Peng; Sasa Dimitrijevic; Brian J Druker; Christopher L Corless; Christopher D M Fletcher; Heikki Joensuu
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
The New England journal of medicine 2002;347(7):472-80.
2002: Renaud Capdeville; Elisabeth Buchdunger; Juerg Zimmermann; Alex Matter
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.
Nature reviews. Drug discovery 2002;1(7):493-502.
2002: Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Terry L Smith; Francis Giles; Stefan Faderl; Deborah A Thomas; Guillermo Garcia-Manero; Jean-Pierre J Issa; Michael Andreeff; Steven M Kornblau; Charles Koller; Miloslav Beran; Michael Keating; Mary Beth Rios; Jianqin Shan; Debra Resta; Renaud Capdeville; Kimberly Hayes; Maher Albitar; Emil J Freireich; Jorge E Cortes
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2177-87.
2002: Hagop M Kantarjian; Susan O'Brien; Jorge E Cortes; Terry L Smith; Mary Beth Rios; Jianqin Shan; Ying Yang; Francis Giles; Deborah A Thomas; Stefan Faderl; Guillermo Garcia-Manero; Sima Jeha; William G Wierda; Jean-Pierre J Issa; Steven M Kornblau; Michael Keating; Debra Resta; Renaud Capdeville; Moshe Talpaz
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2167-76.
2002: Lillian L Siu; Eric K Rowinsky; Lisa A Hammond; Geoffrey R Weiss; Manuel Hidalgo; Gary M Clark; Judy Moczygemba; Les Choi; Ron Linnartz; Nicholas C Barbet; Ivo Sklenar; Renaud Capdeville; Gregory Gan; Carl W Porter; Daniel Von Hoff; S Gail Eckhardt
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2157-66.
2002: Stephen G O'Brien; Sara A D Vieira; Samantha Connors; Nick Bown; James Chang; Renaud Capdeville; Junia V Melo
Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation.
Blood 2002;99(9):3465-7.
2002: Moshe Talpaz; Richard T Silver; Brian J Druker; John M Goldman; Carlo Gambacorti-Passerini; françois guilhot; Charles Alan Schiffer; Thomas Fischer; Michael W N Deininger; Anne L Lennard; Andreas Hochhaus; Oliver G Ottmann; Alois Gratwohl; Michele Baccarani; Richard Stone; Sante Tura; Francois-Xavier Mahon; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Hagop M Kantarjian; Charles L Sawyers
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Blood 2002;99(6):1928-37.
2001: Heikki Joensuu; Peter J Roberts; Maarit Sarlomo-Rikala; Leif C Andersson; Pekka Tervahartiala; David A Tuveson; Sandra Silberman; Renaud Capdeville; Sasa Dimitrijevic; Brian J Druker; George D Demetri
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
The New England journal of medicine 2001;344(14):1052-6.
2001: Brian J Druker; Charles L Sawyers; Andrew Lamb; Debra Resta; S F Reese; J M Ford; Renaud Capdeville; Moshe Talpaz
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
The New England journal of medicine 2001;344(14):1038-42.
2001: Brian J Druker; Moshe Talpaz; Debra Resta; B Peng; Elisabeth Buchdunger; J M Ford; NB Lydon; Andrew Lamb; Renaud Capdeville; S Ohno-Jones; Charles L Sawyers
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
The New England journal of medicine 2001;344(14):1031-7.
2000: Robert Paridaens; D R Uges; Nicholas C Barbet; Les Choi; M Seeghers; W T van der Graaf; H J Groen; Herlinde Dumez; I V Buuren; F Muskiet; Renaud Capdeville; A T Oosterom; E G de Vries
A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours.
British journal of cancer 2000;83(5):594-601.
2000: Ferry A L M Eskens; GA Greim; C van Zuylen; I Wolff; LJ Denis; A S T Planting; F A Muskiet; Jantien Wanders; Nicholas C Barbet; Les Choi; Renaud Capdeville; Jaap Verweij; Axel R Hanauske; U Bruntsch
Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1736-43.
2000: H Zhou; Les Choi; H Lau; U Bruntsch; E E Vries; G Eckhardt; A T Oosterom; Jaap Verweij; Horst Schran; Nicholas C Barbet; R Linnartz; Renaud Capdeville
Population pharmacokinetics/toxicodynamics (PK/TD) relationship of SAM486A in phase I studies in patients with advanced cancers.
Journal of clinical pharmacology 2000;40(3):275-83.
2000: Pieter Sonneveld; A Burnett; P Vossebeld; Monique Ben-Am; G Rosenkranz; C Pfister; G Verhoef; A Dekker; G Ossenkoppele; C Ferrant; L Yin; Alois Gratwohl; Tibor J Kovacsovics; E Vellenga; Renaud Capdeville; Bob Löwenberg
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.
The hematology journal : the official journal of the European Haematology Association / EHA 2000;1(6):411-21.